910297-51-7

Basic information

• Product Name: N-Deshydroxyethyl Dasatinib
• Synonyms: N-(2-Chloro-6-methylphenyl)-2-[[2-methyl-6-(1-piperazinyl)-4-pyrimidinyl]amino]-5-thiazolecarboxamide;N-Deshydroxyethyl Dasatinib;Dasatinib metabolite M4;Dasatinib Impurity A
• CAS NO: 910297-51-7
• Molecular Formula: C₂₀H₂₂ClN₇OS
• Molecular Weight: 443.95
• Product Categories: Various Metabolites and Impurities;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 910297-51-7.mol
• Article Data: 20

Chemical Properties

• Melting Point: >300°C
• Appearance: /
• Density: 1.404g/cm³
• Refractive Index: 1.69
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 10.94±0.70(Predicted)
• CAS DataBase Reference: N-Deshydroxyethyl Dasatinib(CAS DataBase Reference)
• NIST Chemistry Reference: N-Deshydroxyethyl Dasatinib(910297-51-7)
• EPA Substance Registry System: N-Deshydroxyethyl Dasatinib(910297-51-7)

Safety Data

• Hazardous Substances Data: 910297-51-7(Hazardous Substances Data)

Usage

Description

N-Deshydroxyethyl Dasatinib is a metabolite of Dasatinib, a small molecule tyrosine kinase inhibitor. It is a pharmaceutical compound with potential applications in the treatment of various cancers and immune diseases.

Uses

Used in Oncology:
N-Deshydroxyethyl Dasatinib is used as an anticancer agent for the treatment of various types of cancers. It targets specific tyrosine kinases involved in cancer cell growth and proliferation, thereby inhibiting tumor progression.
Used in Immunology:
N-Deshydroxyethyl Dasatinib is also used in the treatment of immune diseases, as it can modulate the immune system's response and potentially alleviate autoimmune conditions.
Used in COVID-19 Research:
N-Deshydroxyethyl Dasatinib is a COVID-19-related research product, indicating its potential use in studying and treating the novel coronavirus disease. Its role in this context may involve targeting specific pathways or mechanisms related to the virus's impact on the human body.

InChI:InChI=1/C20H22ClN7OS/c1-12-4-3-5-14(21)18(12)27-19(29)15-11-23-20(30-15)26-16-10-17(25-13(2)24-16)28-8-6-22-7-9-28/h3-5,10-11,22H,6-9H2,1-2H3,(H,27,29)(H,23,24,25,26)

Upstream product

• 302964-06-3 [5-(2-chloro-6-methylphenylcarbamoyl)thiazol-2-yl]-carbamic acid tert-butyl ester 
• 87-63-8 2-chloro-6-methylaniline 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 302964-08-5 2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide 
• 1780-26-3 2,4-dichloro-2-methylpyrimidine 
• 302964-24-5 2-amino-N-(2-chloro-6-methylphenyl)-1.3-thiazole-5-carboxamide 
• 110-85-0 piperazine 

Downstream Products

• 910297-62-0 ethyl 2-(4-(6-(5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-ylamino)-2-methylpyrimidin-4-yl)piperazin-1-yl)acetate 

Relevant articles and documents

Construction of an IMiD-based azide library as a kit for PROTAC research

As a promising protein degradation strategy, PROTAC technology is increasingly becoming a new star in cancer treatment. Here we report the efficient construction of an IMiD-based azide library via a quick one-step conversion of the existing IMiD-based ami

Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation

Protein degradation is a promising strategy for drug development. Proteolysis-targeting chimeras (PROTACs) hijacking the E3 ligase cereblon (CRBN) exhibit enormous potential and universal degradation performance due to the small molecular weight of CRBN ligands. In this study, the CRBN-recruiting PROTACs were explored on the degradation of oncogenic fusion protein BCR-ABL, which drives the pathogenesis of chronic myeloid leukemia (CML). A series of novel PROTACs were synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide, and the extensive structure-activity relationship (SAR) studies were performed focusing on optimization of linker parameters. Therein, we uncovered that pomalidomide-based degrader 17 (SIAIS056), possessing sulfur-substituted carbon chain linker, exhibits the most potent degradative activity in vitro and favorable pharmacokinetics in vivo. Besides, degrader 17 also degrades a variety of clinically relevant resistance-conferring mutations of BCR-ABL. Furthermore, degrader 17 induces significant tumor regression against K562 xenograft tumors. Our study indicates that 17 as an efficacious BCR-ABL degrader warrants intensive investigation for the future treatment of BCR-ABL+ leukemia.

Compound capable of degrading Bcr-Abl or PARP as well as preparation method and pharmaceutical application thereof

The invention relates to a compound shown in a general formula (Ia), (Ib), (Ic), (Id), (Ie), (If) or (Ig) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal of the compound, an intermediate and a preparation method of the compound, and application of the compound in Bcr-Abl or PARP related diseases such as tumors. The chemical formula is B-K(Ia)B-Cy1-K(Ib)B-Cy1-Cy2-K(Ic)B-Cy1-Cy2-Cy3-K(Id)B-Cy1-Cy2-Cy3-Cy4-K(Ie).